Researchers have identified a gene that causes heart defects in Down syndrome, a condition that results from an additional copy of chromosome 21.
Reducing the overactivity of this gene partially reversed these defects in mice, setting the scene for potential future therapies for heart conditions in people with Down syndrome.
Down syndrome affects around 1 in 800 new births and is caused by an extra third copy of chromosome 21. About half of babies born with Down syndrome have heart defects, such as a failure of the heart to separate into four chambers, leaving a ‘hole in the heart’.
If the heart defects are very serious, high-risk surgery might be needed soon after birth and people often require ongoing monitoring of the heart for the rest of their life. Therefore, better treatment options are needed and this must be guided by knowledge of which of the extra 230 genes on chromosome 21 are responsible for the heart defects. But before this study the identity of these causative genes was not known.
In research published today in Science Translational Medicine, the team studied human Down syndrome fetal hearts as well as embryonic hearts from a mouse model of Down syndrome.
Using genetic mapping, the researchers identified a gene on human chromosome 21 called Dyrk1a, which causes heart defects when present in three copies in the mouse model of Down syndrome. This gene has previously been linked to cognitive impairment and facial changes in Down syndrome, but its role in heart development was not known.
An extra copy of Dyrk1a turned down the activity of genes required for cell division in the developing heart and the function of the mitochondria, which produce energy for the cells. These changes correlated with a failure to correctly separate the chambers of the heart.
The team found that while Dyrk1a is required in three copies to cause heart defects in mice, it was not sufficient alone. Thus, another unknown gene must also be involved in the origin of heart defects in Down syndrome. The team is currently searching for this second gene.
Dyrk1a codes for an enzyme called DYRK1A. The researchers tested a DYRK1A inhibitor on mice pregnant with pups that model the hearts defects in Down syndrome, as their hearts were forming. When DYRK1A was inhibited, the genetic changes were partially reversed and the heart defects in the pups were less severe.
A Group Leader said: “Our research shows that inhibiting DYRK1A can partially reverse changes in mouse hearts, suggesting that this may be a useful therapeutic approach.
“However, in humans the heart forms in the first 8 weeks of pregnancy, likely before a baby could be screened for Down syndrome, so this would be too early for treatment. The hope is that a DYRK1A inhibitor could have an effect on the heart later in pregnancy, or even better after birth. These are possibilities we are currently investigating.”
This research forms part of the lab’s overall goal to understand the genetics behind all aspects of Down syndrome.
Co-first author, said: “It was remarkable that just restoring the copy number of one gene from 3 to 2 reversed the heart defects in the mouse model for Down syndrome. We’re now aiming to understand which of the other genes on this extra chromosome are involved. Even though Dyrk1a isn’t the only gene involved, it’s clearly a major player in many different aspects of Down syndrome.”
Another co-first author, said: “We don’t yet know why the changes in cell division and mitochondria mean the heart can’t correctly form chambers. Dysfunction in the mitochondria has also been linked to cognitive impairment in Down syndrome, so boosting mitochondrial function could be another promising avenue for therapy.”
Latest News
Molecular mechanisms of som…
By newseditor
Posted 01 Jul
A distinct macrophage popul…
By newseditor
Posted 30 Jun
Sex differences in neurolog…
By newseditor
Posted 30 Jun
A neutralizing antibody blo…
By newseditor
Posted 30 Jun
Novel epigenic editor, CHAR…
By newseditor
Posted 30 Jun
Other Top Stories
Bioengineered blood vessels integrated in patients microvasculature…
Read more
3D-printed transparent skull may provide insight into brain concuss…
Read more
Analysis of communication between different parts of brain
Read more
Precision genetic editing with CRISPR-based 'allelic drive'
Read more
Measuring dopamine/glucose with a new quantum material
Read more
Protocols
Monitoring norepinephrine r…
By newseditor
Posted 01 Jul
BicemuS: A new tool for neu…
By newseditor
Posted 26 Jun
Deciphering spatial domains…
By newseditor
Posted 23 Jun
High-throughput volumetric…
By newseditor
Posted 21 Jun
Bioengineered human colon o…
By newseditor
Posted 14 Jun
Publications
Monitoring melanoma patient…
By newseditor
Posted 30 Jun
Loss of GPR75 protects agai…
By newseditor
Posted 30 Jun
Effects of evening smartpho…
By newseditor
Posted 30 Jun
Antibody-activation of conn…
By newseditor
Posted 30 Jun
Mechanism of chaperone coor…
By newseditor
Posted 29 Jun
Presentations
Myelin plasticity in the ve…
By newseditor
Posted 10 Jun
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar